Group 1 - The core offering of the company includes advanced surgical robots designed for minimally invasive procedures, with a focus on market potential in the surgical robotics sector [1][2] - The company plans to issue 27.72 million H-shares at a price of HKD 43.24 per share, aiming to raise approximately HKD 1.2 billion, with a public offering accounting for 10% of the total shares [1] - The company has received significant interest, with a reported oversubscription of 398 times the public offering amount, indicating strong demand for its shares [1] Group 2 - The product lineup includes the Precision® Multi-Port Surgical Robot and the Precision® Single-Port Surgical Robot, both of which are designed for various surgical applications across urology, gynecology, and general surgery [2] - The company has secured cornerstone investment agreements totaling USD 75 million from notable investors, including Tencent and OrbiMed Genesis, which will support the share issuance [2] - The net proceeds from the global offering are expected to be approximately HKD 1.1166 billion, with allocations planned for R&D, commercialization, capacity expansion, and potential strategic acquisitions [3]

Group 1 - The company plans to globally offer 27.72 million H-shares, with 2.77 million shares available in Hong Kong and 24.95 million shares for international offering, subject to reallocation and the exercise of the over-allotment option [1] - The offering price is set at HKD 43.24 per share, with a trading unit of 100 shares, and the shares are expected to start trading on January 8, 2026 [1] - The company was established in 2017 and specializes in advanced surgical robots, focusing on the design, development, and manufacturing of surgical robots [2] Group 2 - The company has entered into cornerstone investment agreements, with cornerstone investors agreeing to subscribe for a total of USD 75 million (approximately HKD 583.5 million) of the offered shares [3] - The cornerstone investors include notable entities such as Abu Dhabi Investment Authority, UBS Asset Management, and Tencent Holdings [3] - Assuming no exercise of the over-allotment option and a share price of HKD 43.24, the net proceeds from the global offering are estimated to be approximately HKD 1.1166 billion [4] Group 3 - The company plans to allocate the net proceeds as follows: approximately 23% for the development of the multi-port laparoscopic surgical robot, 19% for the single-port laparoscopic surgical robot, and 20% for the commercialization of core products [4] - Additionally, about 10% will be used to expand production capacity, 8% for other products and in-development products, and 10% for potential strategic acquisitions, investments, or collaborations in the surgical robot industry [4] - The remaining 10% will be allocated for working capital and general corporate purposes [4]

Group 1 - The company, 精锋医疗-B, plans to conduct an initial public offering (IPO) from December 30, 2025, to January 5, 2026, offering 27.72 million H-shares at a price of HKD 43.24 per share, with 10% allocated for Hong Kong and 90% for international sales [1] - The company specializes in advanced surgical robots, having developed products for minimally invasive and non-invasive surgeries, including the 精锋® multi-port laparoscopic surgical robot and the 精锋® single-port laparoscopic surgical robot [1] - The company has reported revenue growth from RMB 48 million in 2023 to RMB 160 million in 2024, with sales costs increasing from RMB 19.6 million to RMB 61.9 million during the same period [2] Group 2 - The company has not achieved profitability, recording net losses of RMB 213 million, RMB 218.5 million, RMB 133 million, and RMB 89.1 million for the years ending December 31, 2023, and 2024, and for the six months ending June 30, 2024, and 2025, respectively, primarily due to R&D expenses [2] - The company anticipates fluctuations in losses as it continues R&D, seeks regulatory approvals, and commercializes its products, with financial performance expected to vary due to uncertainties in clinical trials and commercialization success [3] - The company has secured cornerstone investment agreements totaling USD 75 million from various investors, including OrbiMed Genesis and Tencent, under certain conditions [3] Group 3 - The net proceeds from the global offering are estimated to be approximately HKD 1.1166 billion, with allocations of 42% for ongoing and planned R&D of core products, 20% for commercialization, 10% for capacity expansion, 8% for other products, and 10% for potential strategic acquisitions or investments in the surgical robot industry [4]

深圳市精鋒醫療科技股份有限公司 Shenzhen Edge Medical Co., Ltd. 股份代號 : 2675 （於中華人民共和國註冊成立的股份有限公司） 全球發售 聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 重要提示 重要提示： 閣下如對本文件的任何內容有任何疑問，應尋求獨立專業意見。 Shenzhen Edge Medical Co., Ltd. 深圳市精鋒醫療科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 全球發售 | 全球發售項下的發售股份數目 | ： | 27,722,200股H股（視乎超額配股權行使 | | --- | --- | --- | | 與否而定） | | | | 香港發售股份數目 | ： | 2,772,300股H股（可予重新分配） | | 國際發售股份數目 | ： | 24,949,900股H股（可予重新分配及視乎 | | 超額配股權行使與否而定） | | | | 發售價 | ： | 每股H股43.24港元，另加1.0%經紀 | ...

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as Precision Medical) is advancing in the surgical robotics sector, having successfully passed the listing hearing on the Hong Kong Stock Exchange with Morgan Stanley and Guotai Junan Securities as joint sponsors [1][3]. Company Overview - Precision Medical specializes in the design, development, and manufacturing of surgical robots, with a product lineup that includes three models at different stages of research and development, targeting the market potential of surgical robots [3]. - The company's core products include the Precision® Multi-Port Laparoscopic Surgical Robot and the Precision® Single-Port Laparoscopic Surgical Robot, along with the Precision® Bronchoscopy Robot, which is not a core product [3]. Product Details - The Precision® Multi-Port Laparoscopic Surgical Robot is designed for minimally invasive surgeries, utilizing robotic, imaging, and digital technologies across urology, gynecology, general surgery, and thoracic surgery [3]. - The Precision® Single-Port Laparoscopic Surgical Robot facilitates minimally invasive surgeries through a single small incision or natural orifice, applicable in urology, gynecology, and general surgery [3]. Market Position - According to Frost & Sullivan, Precision Medical is the first company in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [4]. Financial Performance - For the fiscal years ending June 30, 2023, and June 30, 2024, Precision Medical reported revenues of approximately RMB 48.04 million and RMB 159.99 million, respectively, with net losses of approximately RMB 213 million and RMB 219 million for the same periods [4][6]. - The company anticipates revenues of RMB 30.25 million and RMB 149.38 million for the six months ending June 30, 2024, and 2025, respectively, with corresponding losses of RMB 132.09 million and RMB 89.09 million [4][7].